Jetstream Venture Fund Backs Rejuvenate Bio in Longevity Push

Rejuvenate Bio, a spinoff from Dr. George Church’s Harvard Medical School laboratory, is developing a gene therapy platform designed to treat chronic conditions at the cellular level. Rather than managing symptoms, the company focuses on single-dose treatments for heart failure and metabolic diseases. Its lead human program, RJB-0402, targets inherited heart conditions, while its animal health initiatives provide a dual-purpose strategy for generating revenue while validating human-focused technologies.

For Jetstream, the partnership serves as a proof-of-concept for its interval fund model. By removing the high carried interest fees and significant capital minimums typical of traditional venture capital, the firm provides retail access to Series A opportunities. According to portfolio manager Doug Sylvester, the goal is to bridge the gap between mainstream investors and the exclusive, high-growth startups currently backed by industry giants like Merck and VCapital.